NewAmsterdam Pharma Corporation ads

New at #AHA25: Don’t miss our CSO John Kastelein's oral presentation on an analysis of pooled LDL particle data from our Phase 3 program evaluating our investigational CETP inhibitor. Make sure this session is part of your conference plan.

LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk. Learn about each of these factors:

Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals.

A recent study found only ~40% of ASCVD patients achieved guideline-recommended LDL-C targets, highlighting the need for frequent follow-up, patient counseling, and combination therapies. Learn more about the unmet need in cardiovascular disease.

We are excited to announce that our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. These data were first presented at #AAIC2025. 🔓 Read the open access article: https://lnkd.in/e75tQ3EA

ASCVD risk reduction begins with lowering LDL-C, but residual cardiovascular risk remains and contributes to 400,000 deaths in the US each year. To change that trajectory, we’re challenging ourselves to expect more from dyslipidemia therapies. Visit our newly updated site: